© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
mutant KRASG12C allosteric covalent inhibitor
orally efficacious in XG model
from optimization of literature starting point
J. Med. Chem. Feb. 5, 2020
AstraZeneca, Cambridge, UK
KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.